Safety and Efficacy of Anti-CD38 Therapy (Isatuximab) for Antibody Mediated Rejection in Kidney Transplantation (WTC 2025) - Jul 30, 2025 - Abstract #P2.07.203; Pres time: Aug 4, 2025; 03:30 PM - 04:30 PM; Location: Exhibit Hall AB; "We excluded patients with serum creatinine >2 mg/dl or eGFR 6 on biopsy, significant leukopenia (WBC less than 2), significant viral infections (BK, CMV, Covid requiring hospitalization) within the last 6 months and planned treatment with rituximab or plasmapheresis...Maintenance IS included Tacrolimus with goal trough of 6-8, MMF 1000 mg bid and Prednisone 5 mg...Valacyclovir prophylaxis was used for all patients with plans to use Valganciclovir or Letermovir for CMV high risk patients.* Four patients met the criteria for treatment with isatuximab in 3 months... Anti-CD38 therapy protocol for chronic AMR was incorporated at our center. The infusions were tolerated well by the patients with no infusion related or infection issues. We intend to follow up the eGFR, proteinuria, DSA, cell free DNA and histopathological changes 6 months after treatment and present at the conference."
Clinical • IO biomarker • Antibody-mediated Rejection • Hematological Disorders • Infectious Disease • Leukopenia • Novel Coronavirus Disease • Transplantation
|
|
A. Bhalla; R. Sandhu; N. Goes
|